Pyxis Oncology, Inc.

PYXS

NASDAQ

Healthcare

Biotechnology

Boston, MA, US44 employeespyxisoncology.com

$1.49

+0.02(1.36%)

Mkt Cap $94M

$0.88

$5.34

52-Week Range

At a Glance

AI-generated

Pyxis Oncology, Inc.

Revenue breakdown: Sale Of Royalty Rights (63.5%), Royalty (27.1%), Milestone Revenue (9.4%).

8-K

Pyxis Oncology reported full year 2025 financial results with total revenues of $13.9 million, net loss of $79.6 million or ($1.28) per share, and cash position of $68.3 million sufficient to fund operations into Q4 2026. The company completed target enrollment in the Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC and announced leadership appointments.

$94M

Market Cap

$14M

Revenue

-$80M

Net Income

Employees44

Fundamentals

How The Business Makes Money

Revenue by Segment

Sale Of Royalty Rights63.5%($38M)

Royalty27.1%($16M)

Milestone Revenue9.4%($6M)

Activity

What Changed Recently

Management Change

Feb 5, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective F

Financial Results

Mar 22, 2026

Results of Operations and Financial Condition. On March 23, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results f

Peer Companies

Company	Price	Change	Market Cap	P/E
AVIRAtea Pharmaceuticals, Inc...	$5.75	+1.86%	$459M	-2.7
ZURAZura Bio Limited	$6.05	+0.41%	$394M	-5.3
ENTAEnanta Pharmaceuticals, I...	$13.15	+1.39%	$305M	-3.8
FHTXFoghorn Therapeutics Inc.	$4.93	+0.61%	$289M	-4.3
VYGRVoyager Therapeutics, Inc...	$3.94	-1.13%	$235M	-1.9
IMRXImmuneering Corporation	$5.45	+2.25%	$198M	-4.0
CRBUCaribou Biosciences, Inc.	$1.94	-2.76%	$187M	-1.2
TNYATenaya Therapeutics, Inc.	$0.70	+2.16%	$116M	-1.3

Analyst View

Company Profile

CIK0001782223

ISINUS7473241013

CUSIP747324101

Phone617 221 9059

Address35 Cambridgepark Drive, Boston, MA, 02140, US

SEC EDGAR